Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Sodium Morrhuate”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed2004

Sclerotherapy of oral and facial venous malformations with use of pingyangmycin and/or sodium morrhuate.

Two hundred and sixty patients with oral and facial venous malformations received intralesional injections of either pingyangmycin, sodium morrhuate, or pingyangmycin alternating with sodium morrhuate. Results were rated excellent, good, fair, or poor, depending on clinical outcome. The prevalence of an "excellent" rating in the combined sclerotherapy group (82%) was higher than that in the pingyangmycin group (71%) and the sodium morrhuate group (61%). Swelling and pain following injection were commonly associated with the use of sodium morrhuate. Sclerotherapy with pingyangmycin or sodium morrhuate is an effective and safe treatment for oral and facial venous malformations. Alternate injection of pingyangmycin and sodium morrhuate appears to be more effective for venous malformations than using sclerosant alone.

Angiogenesis Inhibitors↗
PubMed1985

Morphological and biochemical effects of sodium morrhuate on tendons.

The purpose of this study was to determine some of the morphological and biochemical effects of sodium morrhuate injections into intact rabbit patellar tendons and Achilles tendons. The effects of one, three, and five 100 microliters injections of sodium morrhuate on tendon circumference, cell content, collagen fibril diameter, collagen-proteoglycan relationships, water content, amino sugar content, and hydroxyproline content were investigated over periods of 1, 4, and 9 weeks. In general, sodium morrhuate injected tendons were larger in diameter and contained more cells, smaller collagen fibrils, increased water and amino sugar content, and reduced hydroxyproline content compared with their contralateral controls. As a sclerosing agent, sodium morrhuate appears to mimic the early stages of an injury-repair sequence when injected directly into intact tendons. Whether sodium morrhuate may hasten repair responses or improve joint laxity remains to be determined.

Achilles Tendon↗
PubMed1986

Sodium morrhuate delivery to the lung during endoscopic variceal sclerotherapy.

We determined quantitatively the amount of sodium morrhuate that reaches the pulmonary vascular bed during endoscopic variceal sclerotherapy to ascertain whether this affects the diffusing capacity of the lung to carbon monoxide (DLCO). Eleven patients had measurements of DLCO and specific diffusing capacity (DLCO/VA) before and after sclerotherapy. In ten of these patients sclerotherapy was done using sodium morrhuate mixed with 99mTc-labeled albumin microspheres followed by quantitative radionuclide scanning. Most of the sodium morrhuate, 80 +/- 18% (SD) of the total dose, remained in the region of the esophagus. Only 20% of the injected dose reached the pulmonary circulation. There were no changes in DLCO or DLCO/VA. We conclude that most of the sclerosing solution injected during endoscopic variceal sclerotherapy remains at the site of injection. As a result, the pulmonary endothelium is exposed to small amounts of sodium morrhuate and no change in diffusing capacity occurs.

Adult↗
PubMed1985

Sodium morrhuate stimulates granulocytes and damages erythrocytes and endothelial cells: probable mechanism of an adverse reaction during sclerotherapy.

Stimulated by a patient with dyspnea, thrombocytopenia, and leukopenia after sodium morrhuate sclerotherapy, we studied the effect of this agent on the plasma coagulation and complement systems, the formed elements of the blood, and cultured human endothelial cells. The addition of sodium morrhuate to citrated plasma did not cause clotting or shorten the prothrombin time or partial thromboplastin time. Incubation of a 1:100 dilution of the clinical sodium morrhuate preparation in heparinized plasma led to a modest rise in [C3a]. The addition of the drug (dilutions 1:50 to 1:300) to granulocytes caused prompt aggregation (and, at the higher concentrations, granulocyte cytotoxicity [trypan blue exclusion; lactate dehydrogenase release]), but the same dilutions failed to aggregate platelets. However, 0.05% morrhuate added to washed red blood cells caused a prompt 84.0% (+/- 0.8% SEM) hemolysis, rendering the supernatant buffer a potent platelet aggregant. Not only was this sclerosing agent toxic to granulocytes and red cells, but a 1:1000 dilution of the drug also caused the destruction of 35.5% (+/- 6.6%) of cultured endothelial cells as measured by chromium 51 release. Three other agents in current use (ethanolamine oleate, sodium tetradecyl sulfate, and polidocanol) were studied and found to cause effects qualitatively similar to those of sodium morrhuate. We conclude that these drugs cause phlebosclerosis not primarily through induction of plasma coagulation, but by directly damaging endothelium and red cells, triggering platelets, and aggregating granulocytes at the venous wall endothelium. These effects likely derive from the surfactant properties of sodium morrhuate as well as its high arachidonate content.(ABSTRACT TRUNCATED AT 250 WORDS)

Blood Coagulation↗
PubMed1991

A comparison of sclerosing agents. Clinical and histologic effects of intravascular sodium morrhuate, ethanolamine oleate, hypertonic saline (11.7%), and sclerodex in the dorsal rabbit ear vein.

The dorsal marginal rabbit ear vein was injected with 0.25 mL of 2.5, 1, or 0.5% sodium morrhuate, 2.5, 1, or 0.5% ethanolamine oleate, hypertonic saline 11.7%, or Sclerodex. Only the vessel injected with 2.5% sodium morrhuate demonstrated clinical and histologic evidence of endosclerosis with microangiopathic recanalization; 2.5% ethanolamine oleate demonstrated partial clinical sclerosis and luminal recanalization histologically. All other evaluated solutions except 0.5% ethanolamine oleate produced immediate clinical and histologic endothelial damage and thrombosis. However, these latter solutions did not produce sufficient endothelial damage to cause endosclerosis. Extravasated red blood cells occurred in vessels injected with 1 and 2.5% ethanolamine oleate and 1 and 2.5% sodium morrhuate at 1 hour and 2 days, but not in vessels injected with sodium morrhuate 0.5%, ethanolamine oleate 0.5%, Sclerodex, or hypertonic saline 11.7%. Hemosiderin discoloration was not apparent clinically. Cutaneous necrosis was not observed with any of the evaluated solutions.

Animals↗
PubMed1983

Acute respiratory failure after sodium morrhuate esophageal sclerotherapy.

Two of 30 patients with esophageal varices had respiratory distress develop within 8-24 h of esophageal sclerotherapy. Evidence of aspiration and sepsis were absent in these two patients with the clinical picture of adult respiratory distress syndrome. To investigate the possible etiologic role of sodium morrhuate in this syndrome, a sheep model was established and pulmonary hemodynamics, lung lymph flow, and albumin concentration were measured before and after the intravenous injection of 2.5-15.0 cm3 of sodium morrhuate. In all 8 animals studied, mean pulmonary artery pressures increased from 11.6 +/- 2.8 to 32.8 +/- 4.9 mmHg (p less than 0.01) 30 s after injection. These pressures returned to baseline values over 120 min. Lymph flow increased from 0.91 +/- 0.89 to 2.8 +/- 1.5 ml/30 min at 90 min postinjection (p less than 0.05) and returned to baseline values in animals monitored for 6-8 h. The lymph/plasma albumin ratio decreased from 0.856 +/- 0.08 to 0.74 +/- 0.01 (p less than 0.05) 120 min postinjection. Pulmonary edema was not evident histologically or gravimetrically (wet/dry weight ratio was 3.65 +/- 0.3 and not different from normal). It was concluded that sodium morrhuate injection in sheep causes marked but transient pulmonary hypertension associated with an increased lymph flow of relatively protein-poor lymph. Sodium morrhuate esophageal sclerotherapy may affect pulmonary hemodynamics and contribute to respiratory difficulties in patients.

Animals↗
PubMed1985

The hemodynamic effects of the sclerosant sodium morrhuate in dogs.

The hemodynamic effects of systemic administration of 5 per cent sodium morrhuate was evaluated in normal dogs. Dogs in the control group were injected with 2 per cent benzyl alcohol with pH adjusted to 9.5. Animals injected with sodium morrhuate had a significant reduction in cardiac output, arterial blood pressure, portal vein and hepatic artery flows. These changes occurred primarily in the first 30 minutes of observation. In response to the reduction of the hepatic blood flow, there was an increase in portal vein pressure and resistance.

Animals↗
PubMed2003

[The effect of pinyangmycin, dexamethasonum and sodium morrhuate injected concomitantly to treat cavernous hemangioma].

OBJECTIVE: The effect of Pinyangmycin, Dexamethasonum and Sodium Morrhuate injected concomitantly to treat cavernous hemangioma in oral and maxillofacial regions was evaluated. METHODS: The medical records of 350 patients with cavernous hemangioma in oral and maxillofacial regions between January 1998 and January 2002 were reviewed. One hundred and sixty-five of the patients were men, and 185 were women, the sex ratio was 1:1.12. The patients' ages were between 4 months and 55 years. Two hundred and Twenty-six hemangiomas were located in the maxillofacial regions, and 124 located in the oral cavity. The size of the lesions varied from 1 cm x 1 cm to 6 cm x 9 cm. Pinyangmycin, Dexamethasonum and Sodium Morrhuate were injected simultaneously into the lesions or in the vicinity of the cavernous hemangiomas, and the injection might be repeated every 5 to 7 days when necessary, and this process could be repeated 3 to 5 times. RESULTS: Three hundred and fifty patients were followed up for 6-48 months. The cure and essentially cured rates were 95.48%, the total efficiency rate was 100%. CONCLUSION: This method was a safe, simple and effective therapy to manage cavernous hemangioma in the oral and maxillofacial regions.

Adolescent↗
PubMed2000

[Effects of pinyangmycin, dexamethasone and sodium morrhuate injection on treatment of cavernous hemangioma in maxillofacial regions].

OBJECTIVE: To evaluate the effects of Pinyangmycin, Dexamethasonum and Sodium morrhuate injected homochronouly on treatment of cavernous hemangioma in maxillofacial regions. METHODS: The medical records of 115 patients with cavernous hemangioma in maxillofacial regions between September, 1996 and September, 1998 were reviewed. Fifty of the patients were men, and 65 were women, with a ratio of 1:1.3. The age of the patients was from 4 months old to 45 years old. 73 of the hemangioma bodies were sited in maxillofacial regions, 42 were sited in oral cavity. The sizes of the lesions varied from 1 cm x 1 cm to 5 cm x 8 cm. Treatment procedure: 1. Preparation: 8 mg Pinyangmycin was dissolved in 5 mg/ml Dexamethasonum and in 4 ml of 1% procain which were ready for use; 2. Injection: 1-5 ml (Pinyangmycin 1.6-8.0 mg) of mixed solution was first injected to the hemangioma, then followed by an injection of 0.5-2.0 ml Sodium morrhuate according to local appearance, size of the tumor and patient's age. Generally, the amount of each injection should not be over 8 mg Pinyangmycin. If the tumor did not subside after an injection, another injection might be repeated every 5-7 days, and this process might be repeated 3-5 times. The total dose of Pinyangmycin should not be over 40 mg. RESULTS: 115 patients were followed up for 6-24 months. 81 of 115 (70.43%) cases were recovered, and 30 (26.09%) cases were basically recovered. 4 (3.48%) cases got improvement. The recovery rate were 96.52%, and the total efficiency was 100%. CONCLUSION: This method may be a safe, simple and effective therapy to cavernous hemangioma in maxillofacial regions.

Adolescent↗
PubMed1995

Collagen metabolism and tooth eruption: the effects of sodium morrhuate infusions on premolar eruption in dogs.

To test the essential contribution to tooth eruption of the known high level of collagen metabolism in the periodontal ligament, we have infused the crypts of erupting premolars in dogs with sodium morrhuate, a compound known to reduce production, hydroxyproline content and maturation of collagen. Infusions of sodium morrhuate early or later in eruption for more than half the period of eruption had no effect on the process evaluated radiographically and clinically. These data, considered together with other studies, suggest that collagen metabolism per se plays no essential role in tooth eruption.

Animals↗
PubMedDate not supplied

Prospective randomized comparison of esophageal variceal sclerotherapy agents: sodium tetradecyl sulfate versus sodium morrhuate.

We designed a prospective randomized study to evaluate differences in efficacy and complication rate between the two most commonly used sclerosing agents, sodium tetradecyl sulfate (STD) and sodium morrhuate (MOR). Of 41 patients with acute index variceal bleeding initially evaluated, 21 were randomized to receive 0.75% STD and 20 to receive 1.6% MOR diluted with 50% dextrose. Overall mortality for the STD group was 38% and that for the MOR group was 25% (NS). Control of acute bleeding was achieved in 86% of the STD patients and 90% of the MOR patients (NS). Overall, obliteration was achieved in only 33% of the STD group and 25% of the MOR group; but in those patients who remained in the study over 3 months, obliteration was achieved in 87 and 83%, respectively (NS). There was a trend toward higher rebleeding in the STD group compared with the MOR group (81% vs. 51%) (p = 0.078), but there was no significant difference between the STD and MOR patients with regard to transfusion requirements (8.4 units/patient vs. 8.7 units/patient), ulceration (53% vs. 40%), or stricture formation (9.5% vs. 0.0%). The results of this study suggest that STD and MOR are clinically equivalent sclerosing solutions, and that bias favoring use of one agent over the other may be unfounded.

Esophageal and Gastric Varices↗
PubMed1994

Intra-articular treatment of rheumatoid knee-joint effusion with triamcinolone hexacetonide versus sodium morrhuate. A prospective study.

Thirty-one patients with knee effusions associated with rheumatoid arthritis (RA) have been treated with two intraarticular (i.a.) injections of each 330 mg sodium morrhuate (SM) used for synoviorthesis versus a single injection of 20 mg triamcinolone hexacetonide (TA). During an observation period of one year, five articular parameters as well as patient's and doctor's global assessments were evaluated. TA showed an earlier onset and a longer duration of therapeutic effects with high statistical significance. The maximum improvement was significantly more pronounced with TA than with SM. Finally after one year improvement measured by a remission index was observed in 81% versus 33% resp. of all joints injected. Due to ineffectiveness of the primary treatment nine patients (60%) out of the SM group, but not patient out of the TA group had to be crossed over to the other treatment. SM usually caused a reactive effusion within hours after injection requiring arthrocentesis. In conclusion efficacy and tolerability are clearly better for TA than for SM.

Adult↗
PubMedDate not supplied

Comparative effects of 5% ethanolamine oleate versus 5% sodium morrhuate for sclerotherapy of oesophageal varices.

Forty-five cirrhotic patients with oesophageal varices were randomized to receive endoscopic injection sclerotherapy with either 5% ethanolamine oleate (EO), or 5% sodium morrhuate (SM). In the EO group, there was a statistically significant higher rate of disappearance of red colour signs on the varices a week after the initial session of sclerotherapy than in the SM group (91.3% vs 45.5%, P less than 0.05). A jet-like bleeding from injection sites at the second session of sclerotherapy occurred in three patients in the SM group and they experienced blurred vision. There was no such occurrence in the EO group. Oesophageal bleeding requiring blood transfusion during the course of repeated sclerotherapy occurred only in the SM group (five patients): bleeding was from a partly thrombosed varix and in four was from oesophageal ulcers. We found that EO administered intravariceally is more efficacious than SM for sclerotherapy of oesophageal varices.

Esophageal and Gastric Varices↗
PubMed1996

[Clinical summary of relatively large dose of sodium morrhuate injection for the treatment of maxillofacial cavernous hemangionma:A report of 764 cases]

The result of relatively large dose of 5% sodium morrhuate injection(SIM) for the treatment of 764 cases in the cavernous hemangioma in orofacial region is presented.The curative rate was improved,Its cure and elementary cure rate were 89.27%.The dosage,course and practical approach were discussed,The relationship of factors listed above with the curative effect were mentioned.The reaction and complications might be influencing the recurrence rate.Hemangioma after SMI should be observed in order to consolidate its curative effect.

Journal Article↗